# Dalteparin in Preventing DVT in Participants With Cancer

> **NCT00525057** · NA · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 65 (actual)

## Conditions studied

- Bone Sarcoma
- Femur Fracture
- Lymphoma
- Metastatic Neoplasm
- Pathologic Fracture
- Plasma Cell Myeloma
- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Dalteparin

## Key facts

- **NCT ID:** NCT00525057
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-07
- **Primary completion:** 2020-06-19
- **Final completion:** 2020-06-19
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00525057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00525057, "Dalteparin in Preventing DVT in Participants With Cancer". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00525057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*